On July 31, 2020 the U.S. Food and Drug Administration (FDA) announced it has approved tafasitamab-cxix (MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic antibody, in
Read More >
Lymphoma Research Foundation Elects Allison+Partners Co-Founder Scott Pansky to Esteemed Board
Read More >
The American Board of Internal Medicine (ABIM) has ABIM has 12 Specialty Boards – one for all disciplines solely sponsored and administered by ABIM. The Specialty Boards are where the frontline work at the discipline-specific level is done.
Read More >Brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company) has been approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first chimeric antigen receptor (CAR) T cell therapy approved for MCL.
Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.
Read More >
